Terms: = Breast cancer AND FGFR4, CD334, 2264, ENSG00000160867, P22455, MGC20292, TKF, JTK2
124 results:
1. Design, synthesis, and biological evaluation of selective covalent inhibitors of fgfr4.
Chen X; Li H; Lin Q; Dai S; Qu L; Guo M; Zhang L; Liao J; Wei H; Xu G; Jiang L; Chen Y
Eur J Med Chem; 2024 Mar; 268():116281. PubMed ID: 38432058
[TBL] [Abstract] [Full Text] [Related]
2. Insight into the design of fgfr4 selective inhibitors in cancer therapy: Prospects and challenges.
Chen X; Huang Y; Chen B; Liu H; Cai Y; Yang Y
Eur J Med Chem; 2024 Jan; 263():115947. PubMed ID: 37976704
[TBL] [Abstract] [Full Text] [Related]
3. External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer.
Wang Y; Broeks A; Giardiello D; Hauptmann M; Jóźwiak K; Koop EA; Opdam M; Siesling S; Sonke GS; Stathonikos N; Ter Hoeve ND; van der Wall E; van Deurzen CHM; van Diest PJ; Voogd AC; Vreuls W; Linn SC; Dackus GMHE; Schmidt MK
Eur J Cancer; 2023 Dec; 195():113401. PubMed ID: 37925965
[TBL] [Abstract] [Full Text] [Related]
4. FGF2 drives osteosarcoma metastasis through activating FGFR1-4 receptor pathway-mediated ICAM-1 expression.
Huang YC; Chen WC; Yu CL; Chang TK; I-Chin Wei A; Chang TM; Liu JF; Wang SW
Biochem Pharmacol; 2023 Dec; 218():115853. PubMed ID: 37832794
[TBL] [Abstract] [Full Text] [Related]
5. Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer.
Dai LJ; Ma D; Xu YZ; Li M; Li YW; Xiao Y; Jin X; Wu SY; Zhao YX; Wang H; Yang WT; Jiang YZ; Shao ZM
Nat Commun; 2023 Aug; 14(1):5112. PubMed ID: 37607916
[TBL] [Abstract] [Full Text] [Related]
6. Triple-negative breast Carcinoma With Apocrine and Histiocytoid Features: A Clinicopathologic and Molecular Study of 18 Cases.
Wang Y; Hacking SM; Li Z; Graff SL; Yang D; Tan L; Liu F; Zhang T; Zhao Z; Luo S; Du P; Jia S; Cheng L
Am J Surg Pathol; 2023 Sep; 47(9):1011-1018. PubMed ID: 37310016
[TBL] [Abstract] [Full Text] [Related]
7. Alpinumisoflavone against cancer pro-angiogenic targets: In silico, In vitro, and In ovo evaluation.
Alos HC; Billones JB; Castillo AL; Vasquez RD
Daru; 2022 Dec; 30(2):273-288. PubMed ID: 35925539
[TBL] [Abstract] [Full Text] [Related]
8. Mutational landscape of primary breast angiosarcoma with repeated resection and recurrence over a 15-year period: A case report.
Teruyama F; Kuno A; Murata Y; Nakagawa T; Shiba-Ishii A; Yuguchi S; Noguchi M
Pathol Int; 2022 Sep; 72(9):457-463. PubMed ID: 35801418
[TBL] [Abstract] [Full Text] [Related]
9. N6-methyladenosine regulated fgfr4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer.
Zou Y; Zheng S; Xie X; Ye F; Hu X; Tian Z; Yan SM; Yang L; Kong Y; Tang Y; Tian W; Xie J; Deng X; Zeng Y; Chen ZS; Tang H; Xie X
Nat Commun; 2022 May; 13(1):2672. PubMed ID: 35562334
[TBL] [Abstract] [Full Text] [Related]
10. Discovery of Novel 7-Azaindole Derivatives as Selective Covalent Fibroblast Growth Factor Receptor 4 Inhibitors for the Treatment of Hepatocellular Carcinoma.
Zhong Z; Shi L; Fu T; Huang J; Pan Z
J Med Chem; 2022 May; 65(10):7278-7295. PubMed ID: 35549181
[TBL] [Abstract] [Full Text] [Related]
11. Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer.
Silvestri M; Dugo M; Vismara M; De Cecco L; Lanzoni D; Vingiani A; Folli S; De Santis MC; de Braud F; Pruneri G; Di Cosimo S; Cappelletti V
Sci Rep; 2022 Jan; 12(1):1470. PubMed ID: 35087134
[TBL] [Abstract] [Full Text] [Related]
12. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models.
Chew NJ; Lim Kam Sian TCC; Nguyen EV; Shin SY; Yang J; Hui MN; Deng N; McLean CA; Welm AL; Lim E; Gregory P; Nottle T; Lang T; Vereker M; Richardson G; Kerr G; Micati D; Jardé T; Abud HE; Lee RS; Swarbrick A; Daly RJ
Breast Cancer Res; 2021 Aug; 23(1):82. PubMed ID: 34344433
[TBL] [Abstract] [Full Text] [Related]
13. Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancer.
Schettini F; Barbao P; Brasó-Maristany F; Galván P; Martínez D; Paré L; De Placido S; Prat A; Guedan S
ESMO Open; 2021 Jun; 6(3):100102. PubMed ID: 33838601
[TBL] [Abstract] [Full Text] [Related]
14. Effects of fgfr4 G388R, V10I polymorphisms on the likelihood of cancer.
Peng T; Sun Y; Lv Z; Zhang Z; Su Q; Wu H; Zhang W; Yuan W; Zuo L; Shi L; Zhang LF; Zhou X; Mi Y
Sci Rep; 2021 Jan; 11(1):1373. PubMed ID: 33446698
[TBL] [Abstract] [Full Text] [Related]
15. Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences.
Priedigkeit N; Ding K; Horne W; Kolls JK; Du T; Lucas PC; Blohmer JU; Denkert C; Machleidt A; Ingold-Heppner B; Oesterreich S; Lee AV
Breast Cancer Res; 2021 Jan; 23(1):1. PubMed ID: 33407744
[TBL] [Abstract] [Full Text] [Related]
16. [Protection of nerve function during transoral endoscopic thyroidectomy by vestibular approach].
Wu Z; Fang JG; Chen X; Hou LZ; Zhong Q; Ma HZ; Zhang Y; Shen XX
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Oct; 55(10):893-898. PubMed ID: 33036502
[No Abstract] [Full Text] [Related]
17. Loss of progesterone receptor is associated with distinct tyrosine kinase profiles in breast cancer.
Tahiri A; Tekpli X; Satheesh SV; DeWijn R; Lüders T; Bukholm IR; Hurtado A; Geisler J; Kristensen VN
Breast Cancer Res Treat; 2020 Oct; 183(3):585-598. PubMed ID: 32710281
[TBL] [Abstract] [Full Text] [Related]
18. fgfr4 Gly388Arg Polymorphism Affects the Progression of Gastric cancer by Activating STAT3 Pathway to Induce Epithelial to Mesenchymal Transition.
Ye Y; Li J; Jiang D; Li J; Xiao C; Li Y; Han C; Zhao C
Cancer Res Treat; 2020 Oct; 52(4):1162-1177. PubMed ID: 32599983
[TBL] [Abstract] [Full Text] [Related]
19. fgfr4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease.
Garcia-Recio S; Thennavan A; East MP; Parker JS; Cejalvo JM; Garay JP; Hollern DP; He X; Mott KR; Galván P; Fan C; Selitsky SR; Coffey AR; Marron D; Brasó-Maristany F; Burgués O; Albanell J; Rojo F; Lluch A; de Dueñas EM; Rosen JM; Johnson GL; Carey LA; Prat A; Perou CM
J Clin Invest; 2020 Sep; 130(9):4871-4887. PubMed ID: 32573490
[TBL] [Abstract] [Full Text] [Related]
20. fgfr4: A promising therapeutic target for breast cancer and other solid tumors.
Levine KM; Ding K; Chen L; Oesterreich S
Pharmacol Ther; 2020 Oct; 214():107590. PubMed ID: 32492514
[TBL] [Abstract] [Full Text] [Related]
[Next]
